Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom's Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...
Basel-based biotech Nouscom has raised €67.5 million ($72.2 million) to bankroll its cancer vaccines as the eight-year-old company looks to capitalize on momentum in the field.
Nouscom™s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential
ProBioGen announces that their proprietary vaccine production cell line AGE1.CR.pIX has been successfully used to manufacture a viral vector product that has advanced into a randomized phase II clinical trial. Nouscom has in-licensed ProBioGen's platform technology for the GMP production of a component of their neoantigen targeting cancer vaccine, Nous-209 targeting Microsatellite Instable High (MSI-H) solid tumors.
Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
BASEL, Switzerland, Jan. 5, 2023 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to evaluate Nouscom's wholly-owned lead candidate, NOUS-209, in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) versus KEYTRUDA alone in randomized Phase 2 trials in patients with Mismatch Repair/Microsatellite Instable High (dMMR/MSI-H) Metastatic Colorectal Cancer (CRC).
Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer
Nouscom announces leading publication revealing an immune mechanism of action
BASEL, Switzerland, June 6, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced first data from the completed Phase 1 trial evaluating NOUS-209 in combination with anti-PD-1 checkpoint inhibitor (pembrolizumab). The data, presented yesterday in a poster discussion session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated NOUS-209 to be safe, highly immunogenic and with promising signs of clinical efficacy.
BASEL, Switzerland, May 27, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced that full data obtained from the Phase 1 trial evaluating NOUS-209 has been accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held virtually and in person in Chicago from 3 to 7th June.